Reshma Kewalramani

President, CEO, and Director at VERTEX PHARMACEUTICALS INC / MA

Board

Since April 2020

Age

52 years

Education

Earned a B.A. and M.D. from Boston University School of Medicine and completed the General Management Program at Harvard Business School.

Tenure

Joined Vertex in February 2017 as Senior Vice President, Late Development, was promoted to Executive Vice President and Chief Medical Officer in April 2018, and advanced to President, CEO, and Director in April 2020.

Also at VERTEX PHARMACEUTICALS INC / MA

JML

Jeffrey M. Leiden

Executive Chairman

CFWJ

Charles F. Wagner, Jr.

Executive Vice President and CFO

DJM

Duncan J. McKechnie

Senior Vice President, Head of North America Commercial

About

Dr. Reshma Kewalramani holds a strong academic foundation with a B.A. and M.D. from Boston University School of Medicine, complemented by the completion of the General Management Program at Harvard Business School. She also completed her internship, residency, and fellowship at prestigious institutions including Massachusetts General Hospital and Brigham and Women’s Hospital.

Starting her tenure at Vertex in February 2017 as Senior Vice President, Late Development, she quickly ascended the leadership ladder by assuming the roles of Executive Vice President and Chief Medical Officer in April 2018 and ultimately becoming the President, CEO, and Director in April 2020. During her time at Vertex, she has played an instrumental role in driving innovation and expanding the company’s pipeline.

Prior to her contributions at Vertex, she built a robust career at Amgen Inc., where she held increasing roles of responsibility, culminating in senior leadership positions. Additionally, her experience as an industry representative to the FDA’s Endocrine and Metabolic Drug Advisory Committee further underscores her influence and commitment in the biotechnology sector.

$VRTX Performance Under Reshma Kewalramani

Past Roles

Organization	Role	Date Range	Details
Ginkgo Bioworks Holdings, Inc.	Board Member	September 2021 - June 2024	Former board membership.
Vertex Pharmaceuticals Incorporated	Executive Vice President and Chief Medical Officer	2018 - March 2020	Position ended upon her promotion to CEO in April 2020.
Vertex Pharmaceuticals Incorporated	Senior Vice President, Late Development	2017 - 2018	Preceded her EVP/CMO role.
Amgen Inc.	Vice President and Head of U.S. Medical Organization	2004 - 2017	Held roles of increasing responsibility culminating in her leadership role.

Fixed Compensation

Data from FY 2023

Component Name	Amount	Payment Schedule	Additional Details
Base Salary	$1,500,000	Annual (2023)	Fixed base salary component
401(k) Match	$14,850	As applicable	Part of All Other Compensation
Life Insurance Premiums	$2,697	As applicable	Included in All Other Compensation
Matching Gift Program	$25,000	As applicable	Included in All Other Compensation
Other	$0	N/A	No additional fixed components reported

Performance Compensation

Data from FY 2023

Annual Cash Bonus

The Annual Cash Bonus for 2023 is calculated based on several performance metrics and targets. Below is a detailed breakdown:

Metric	Value
Base Salary	$1,500,000
Individual Incentive Target	120% of Base Salary
Target Bonus	$1,800,000
Company Performance Factor	150%
Individual Performance Factor	150%
Calculated Bonus Amount	$4,050,000
Payment Schedule	Paid in Q1 2024 for 2023 performance

Calculation: $1,800,000 × 150% × 150% = $4,050,000.

Stock Awards

Reshma Kewalramani’s stock awards for 2023 comprise both Performance Stock Units (PSUs) and Time-Based Restricted Stock Units (RSUs). The details are as follows:

Performance Stock Units (PSUs)

Metric	Details
Target Shares	13,486 shares
Maximum Shares	26,972 shares
Vesting Condition	Vest upon achieving performance objectives (specific thresholds not detailed)

Time-Based Restricted Stock Units (RSUs)

Metric	Details
Grant Date	February 1, 2023
Grant-date Fair Value	$8,572,511
Grant Date Stock Price	Not provided
Vesting Schedule	Vests annually over three years

Additionally, Reshma Kewalramani received a performance rating of "Leading Exemplary" which coupled with the maximum individual performance factor (150%) contributed to the bonus calculation.

These performance compensation components encompass both cash and share-based awards that are contingent upon the achievement of prescribed corporate and individual performance metrics.